All PlansCoverageLow impact
Serum Holo-Transcobalamin as a Marker of Vitamin B12 (i.e., Cobalamin) Status
Blue Cross & Blue Shield of Mississippi·Family Medicine, Internal Medicine, General Practice +2 more·Medical Policy
Effective date
Aug 4, 2025
We identified it
Jun 20, 2026
Summary
This policy confirms that serum holotranscobalamin testing for Vitamin B12 deficiency diagnosis remains investigational and non-covered. The policy was recently reviewed with updated sources but no coverage changes were made.
Action Required
Continue denying claims for holotranscobalamin testing (CPT 84999) as investigational. Advise providers to use standard serum B12 testing or metabolite markers (MMA, homocysteine) for B12 deficiency diagnosis instead.